Overview

HMPL-453 in Advanced Malignant Mesothelioma

Status:
Recruiting

Trial end date:
2023-03-17

Target enrollment:

Participant gender:

Summary

This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 in patient with advanced Malignant Mesothelioma

Phase:

Phase 2

Details

Lead Sponsor:

Hutchison Medipharma Limited